Scholarlink

<p>Antibody-drug conjugate (ADC) therapy has transformed treatment for several solid tumors, including small cell lung cancer (SCLC). However, significant challenges remain, including systemic toxicity, acquired resistance, and the lack of reliable biomarkers for patient selection. To enhance the effectiveness of ADC therapies in SCLC, we focused on target selection in this study by investigating the expression of ADC targets - <i>SEZ6</i>, <i>DLL3</i>, <i>CD276</i>, and <i>TACSTD2 -</i> in cell lines and patient samples. <i>SEZ6</i> expression was significantly elevated in various SCLC transcriptional subtypes, particularly <i>ASCL1</i>, and exhibited gender-specific differences, being lower in women. <i>DLL3</i> was primarily observed in the <i>ASCL1</i> subtype, while <i>CD276</i> showed high expression in non-neuroendocrine subtypes. <i>TACSTD2 levels</i> were generally low and attenuated in lymph nodes and brain metastases compared to primary tumors. Our findings underscore the importance of understanding target expression patterns to optimize ADC therapy and advance precision medicine in SCLC treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Assessment of targets of antibody drug conjugates in SCLC

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月2日

查看全文
  • Abhishek Ajay,
  • Han Wang,
  • Ali Rezvani,
  • Omid Savari,
  • Brandon J. Grubb,
  • Karen S. McColl,
  • Suzy Yoon,
  • Peronne L. Joseph,
  • Shelby R. Kopp,
  • Adam M. Kresak,
  • Craig D. Peacock,
  • Gary M. Wildey,
  • Minh Lam,
  • Masaru Miyagi,
  • Hung-Ying Kao,
  • Afshin Dowlati

摘要

Antibody-drug conjugate (ADC) therapy has transformed treatment for several solid tumors, including small cell lung cancer (SCLC). However, significant challenges remain, including systemic toxicity, acquired resistance, and the lack of reliable biomarkers for patient selection. To enhance the effectiveness of ADC therapies in SCLC, we focused on target selection in this study by investigating the expression of ADC targets - SEZ6, DLL3, CD276, and TACSTD2 - in cell lines and patient samples. SEZ6 expression was significantly elevated in various SCLC transcriptional subtypes, particularly ASCL1, and exhibited gender-specific differences, being lower in women. DLL3 was primarily observed in the ASCL1 subtype, while CD276 showed high expression in non-neuroendocrine subtypes. TACSTD2 levels were generally low and attenuated in lymph nodes and brain metastases compared to primary tumors. Our findings underscore the importance of understanding target expression patterns to optimize ADC therapy and advance precision medicine in SCLC treatment.